Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and nine months ended September 30, 2025
Business Overview: A clinical-stage biotechnology company focused on developing product candidates for diseases involving immune dysfunction. Key platforms include DN-TNF (XPro for Alzheimer's), CORDStrom (for RDEB), and INKmune (for oncology). The company is a smaller reporting company with no commercial revenue to date.
Key Financial Metrics
| Metric (in thousands) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Revenue | $0 | $0 | $50 | $14 |
| Net Loss | $(6,472) | $(12,093) | $(40,669) | $(32,864) |
| Net Loss Per Share (Basic/Diluted) | $(0.24) | $(0.60) | $(1.68) | $(1.71) |
| Operating Expenses | $7,433 | $12,286 | $41,959 | $33,182 |
| Cash and Cash Equivalents (End of Period) | $27,734 | $33,552 | $27,734 | $33,552 |
| Net Cash Used in Operating Activities | N/A | N/A | $(19,638) | $(22,348) |
| Net Cash Provided by Financing Activities | N/A | N/A | $27,545 | $20,289 |
Note: The 9M 2025 operating expenses include a one-time impairment charge of $16.5 million related to the XPro Alzheimer's program.
Material Changes vs. Prior Period
- Net Loss Reduction (Q3): Net loss decreased by $5.6 million in Q3 2025 compared to Q3 2024, primarily driven by a $5.2 million reduction in R&D expenses following the completion of the Phase 2 Alzheimer's trial.
- Impairment Charge (9M): The 9M 2025 net loss increased by $7.8 million compared to the prior year, largely due to a $16.5 million impairment of acquired in-process R&D intangible assets (XPro) recorded in Q2 2025 after the Phase 2 trial failed to meet its primary endpoint.
- Capital Raises: The company raised approximately $27.5 million in net proceeds during the first nine months of 2025 through a registered direct offering ($17.4 million net) and At-The-Market (ATM) offerings ($10.1 million net).
- Debt Status: The company fully repaid its $15 million term loan in December 2024; no debt principal repayments occurred in 2025.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has raised substantial doubt about the company's ability to continue as a going concern. With $27.7 million in cash, the company projects insufficient liquidity to sustain operations for one year following the filing date without additional financing.
- Product Pipeline Updates:
- XPro (Alzheimer's): Phase 2 trial failed primary endpoints in the overall population but showed potential signals in a pre-specified enriched subgroup. Development has been halted due to resource constraints; the company is seeking a partner.
- CORDStrom (RDEB): Received Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) from the FDA. Plans to submit a Biologics License Application (BLA) in 2026.
- INKmune (Oncology): Phase I/II trial in metastatic castrate-resistant prostate cancer is ongoing, with top-line data expected in mid-2026.
- Financing Strategy: The company intends to secure funding through equity sales, debt financing, collaborations, or licensing arrangements. Failure to secure capital could force delays or discontinuation of product development.
- Legal/Contingencies: A vendor dispute regarding $1.6 million in invoiced services was settled in August 2025 for approximately $0.2 million.
Investor Verification Checklist
- Liquidity Runway: Verify the specific timeline for cash depletion and the status of any pending financing agreements or partnership discussions.
- XPro Partnership: Confirm if a partner has been identified to take over the XPro Alzheimer's program, as internal development has ceased.
- CORDStrom Regulatory Path: Monitor the timeline for the planned BLA submission in 2026 and the status of the open-label extension study.
- Dilution Risk: Assess the impact of potential future equity raises required to fund operations, given the current cash burn rate.
- Subgroup Data: Review the detailed analysis of the "enriched subgroup" in the XPro Phase 2 trial to understand the basis for potential future development.